Quick Answer
Lyell Immunopharma, Inc. reported Total Revenue of $36.0 thousand for fiscal year 2025.
Lyell Immunopharma, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $36.0K | -41.0% |
| 2024 | $61.0K | -53.1% |
| 2023 | $130.0K | -99.8% |
| 2022 | $84.68M | +695.1% |
| 2021 | $10.65M | +37.3% |
| 2020 | $7.76M | +1080.5% |
| 2019 | $657.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.0K | -55.9% | +87.5% |
| June 30, 2025 | $8.0K | -38.5% | +14.3% |
| March 31, 2025 | $7.0K | +133.3% | -79.4% |
| September 30, 2024 | $34.0K | +36.0% | +161.5% |
| June 30, 2024 | $13.0K | -51.9% | +333.3% |
| March 31, 2024 | $3.0K | -95.4% | -88.0% |
| September 30, 2023 | $25.0K | +733.3% | -7.4% |
| June 30, 2023 | $27.0K | -99.9% | -58.5% |
- Lyell Immunopharma, Inc. showed a decrease of -41.0% in Total Revenue compared to the prior fiscal year.
- Over the 2019–2025 period, Lyell Immunopharma, Inc.’s total revenue has declined by 94.5% (from $657.0 thousand to $36.0 thousand).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: